930 related articles for article (PubMed ID: 10482195)
1. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
4. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
8. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
9. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
11. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
15. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
zum Büschenfelde CM; Hermann C; Schmidt B; Peschel C; Bernhard H
Cancer Res; 2002 Apr; 62(8):2244-7. PubMed ID: 11956077
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
17. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
19. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
[TBL] [Abstract][Full Text] [Related]
20. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
